Opyl (ASX: OPL) Partners with L39 Capital Pty Ltd to Launch An AI-Driven Biotech Fund Targeting $100M AUM in 36 months

Melbourne, Australia OpylLimited (ASX:OPLor the Company),a leader in AI-driven clinical trial design andoptimisation, today announces a strategic partnership with L39 Capital Pty Ltd (L39), both a party to this deal and the manager of the Biotech Fund (the "Fund")."

Key Highlights:

• Partnership:Opylpartners with L39 Capital Pty Ltd toestablisha Biotech Fund.
• OpylRevenue:Payment of $25,000 in the first 12 months, withadditionalgrowth in revenue as the fund increases in size and performance.
• Funds Under Management Target: $100 milliontarget within36 monthsuncappedgoal.
• OpylEquity Stake and Share:Opylwill also obtain a 19.9% equity stake in the AI Fund Manager and a 25% share of the fees earned by the Fund.
• Agreement Type: Non-exclusive.

This collaboration aims to leverageOpyl'sproprietaryTrialKeytechnology to generate significant capital appreciation for investors. It alsoshowcasesthe predictive power ofTrialKeyin selecting successful biotech and pharmaceutical stocks.

Saurabh Jain, ExecutiveChairmanofOpyl, commented, "This partnership marks a significant milestone forOpyl. By integratingTrialKey'spredictive technology into an investment fund, we are creating a new revenue stream and demonstrating the transformative potential of AI in the biotech and pharmaceutical industries."

Summary of Key Terms of theAgreement

Benefits toOpyland Its Shareholders

• Revenue Generation: The performance fees and equity stake in the Fund Manager will provideOpylwith recurring income, boosting its financial stability and growth potential.This revenue stream will helpOpylsustain its operations and invest in further development of its AI technologies.
• Market Validation: The successful application ofTrialKeyin the Fund will serve as a proof of concept,validatingits predictive capabilities and attracting further interest from the biotech and pharmaceutical sectors. This will positionOpylas a leader in AI-driven clinical trial design and prediction.
• Enhanced Capabilities: The ongoing development and improvement ofTrialKeywill reinforce its position as the gold standard in AI-driven clinical trial design and prediction. The enhancements and intellectual property developed through the Fund willbenefitOpylby expanding the functionality and accuracy ofTrialKey.
• Strategic Growth: By partnering with L39 Capital Pty Ltd,Opylgains access to significantexpertisein fund management and biotech/pharmaceutical trading, accelerating its strategic growth initiatives. This collaboration opens new avenues forOpylto exploreadditionalapplications of its AI technology in financial markets and beyond.L39 has beena strong supporterofOpyl, providingpreviouscapital and backing,demonstratinga belief in our mission and capabilities.
• Improved Investor Confidence: The establishment of the Fund and its target of $100 million in AUM within36 monthswilldemonstratethe robustness and market applicability ofTrialKey. This can enhance investor confidence inOpylstechnology and its potential for broader applications in the biotech and pharmaceutical industries.

About L39 Capital Pty Ltd

L39 Capital Pty Ltd (L39) is a fund manager focused on small-cap companies, both listed and unlisted. Witha diversifiedexperience amongst its four partners, L39 currently manages the L39 Capital Fund, seeking toidentifyhigh-quality businesses led by competent management which are often overlooked by other investors.

This announcement has beenauthorisedfor release by the board

-ENDS-

For investor enquiries:

Bernice Averion

Head of Marketing and Communications

Phone: +61 415 311 957